Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nexium OTC Switch Would Face Crowded Field, Potential Questions

This article was originally published in The Tan Sheet

Executive Summary

Pfizer will pay AstraZeneca $250 million upfront for global rights to market a potential OTC 20-mg Nexium. Pharma marketing expert Joe McGovern expects Nexium “to start OTC with a big bang,” but Center for Consumer Self Care Executive Director Bill Soller points to potential safety questions about a switch.

Advertisement

Related Content

UK Nexium Ad Rapped For Downplaying Treatment For Persistent Heartburn
Orally Dissolving Competition Lurks For Prevacid 24HR, Other OTC PPIs
Orally Dissolving Competition Lurks For Prevacid 24HR, Other OTC PPIs
Ironwood Could Use Linzess As Model For GERD Market
OTC Nexium 24HR Rides Blockbuster History Into Full Field Of Competitors
OTC Nexium 24HR Rides Blockbuster History Into Full Field Of Competitors
Pfizer Expects OTC Nexium Will Launch With Market Exclusivity
Public Citizen Urges FDA To Add Sweeping Warnings To PPI Labels
Lipitor OTC Switch Would Force Pfizer To Clear Big Research Hurdles
Zegerid OTC Approved, Limited To Touting Dual-Ingredient Formula For Now

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS105919

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel